115 related articles for article (PubMed ID: 23871660)
1. Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning.
Haworth A; Williams S; Reynolds H; Waterhouse D; Duchesne GM; Bucci J; Joseph D; Bydder S; Ebert M
Brachytherapy; 2013; 12(6):628-36. PubMed ID: 23871660
[TBL] [Abstract][Full Text] [Related]
2. Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy.
Her EJ; Reynolds HM; Mears C; Williams S; Moorehouse C; Millar JL; Ebert MA; Haworth A
Phys Med Biol; 2018 Jun; 63(13):135011. PubMed ID: 29799812
[TBL] [Abstract][Full Text] [Related]
3. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.
Zaider M; Zelefsky MJ; Lee EK; Zakian KL; Amols HI; Dyke J; Cohen G; Hu Y; Endi AK; Chui C; Koutcher JA
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1085-96. PubMed ID: 10863082
[TBL] [Abstract][Full Text] [Related]
4. Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.
Miksys N; Haidari M; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Med Phys; 2017 Aug; 44(8):4329-4340. PubMed ID: 28455849
[TBL] [Abstract][Full Text] [Related]
5. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
6. A radiobiology-based inverse treatment planning method for optimisation of permanent l-125 prostate implants in focal brachytherapy.
Haworth A; Mears C; Betts JM; Reynolds HM; Tack G; Leo K; Williams S; Ebert MA
Phys Med Biol; 2016 Jan; 61(1):430-44. PubMed ID: 26675313
[TBL] [Abstract][Full Text] [Related]
7. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
8. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
9. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
10. Assessment of i-125 prostate implants by tumor bioeffect.
Haworth A; Ebert M; Waterhouse D; Joseph D; Duchesne G
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1405-13. PubMed ID: 15275726
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.
Mashouf S; Safigholi H; Merino T; Soliman A; Ravi A; Morton G; Song WY
Brachytherapy; 2016; 15(6):774-779. PubMed ID: 27720310
[TBL] [Abstract][Full Text] [Related]
12. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
13. Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: How best to spare the rectum?
Guimas V; Quivrin M; Bertaut A; Martin E; Chambade D; Maingon P; Mazoyer F; Cormier L; Créhange G
Brachytherapy; 2016; 15(4):406-411. PubMed ID: 27317949
[TBL] [Abstract][Full Text] [Related]
14. A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment.
Strigari L; Orlandini LC; Andriani I; d'Angelo A; Stefanacci M; Di Nallo AM; Benassi M
Phys Med Biol; 2008 Sep; 53(18):5045-59. PubMed ID: 18723926
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose.
Wang JZ; Li XA
Med Phys; 2003 Jan; 30(1):34-40. PubMed ID: 12557976
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
Yang R; Zhao N; Liao A; Wang H; Qu A
Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
[TBL] [Abstract][Full Text] [Related]
17. Focal prostate brachytherapy with (103)Pd seeds.
Butler WM; Merrick GS
Phys Med; 2016 Mar; 32(3):459-64. PubMed ID: 27053451
[TBL] [Abstract][Full Text] [Related]
18. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
[TBL] [Abstract][Full Text] [Related]
19. Dosimetry modeling for focal high-dose-rate prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Thwaites D; Henry A
Brachytherapy; 2014; 13(6):611-7. PubMed ID: 25085456
[TBL] [Abstract][Full Text] [Related]
20. Tumor control probability (TCP) in prostate cancer: role of radiobiological parameters and radiation dose escalation.
Ahmad S; Vogds BJ; McKenna F; Vlachaki MT
J Xray Sci Technol; 2009; 17(4):347-54. PubMed ID: 19923690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
